Compare GMEX & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMEX | ADTX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Australia | United States |
| Employees | 16 | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.0K | 641.6K |
| IPO Year | 2023 | 2020 |
| Metric | GMEX | ADTX |
|---|---|---|
| Price | $0.26 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 1.2M |
| Earning Date | 04-17-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,195.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.32 | $0.05 |
| 52 Week High | $1.25 | $7.13 |
| Indicator | GMEX | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 31.49 |
| Support Level | N/A | $0.05 |
| Resistance Level | $0.74 | $1.11 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 4.80 | 7.57 |
GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.